Representational fairness in WTO rule-making: negotiating, implementing, and disputing the TRIPS pharmaceutical-related provisions
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
London
British Institute of International and Comparative Law
2006
[Dallas, Tex.] SMU Dedman School of Law |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | At head of title: British Institute of International and Comparative Law and SMU Dedman School of Law (SMU-London Forum Initiative). Includes bibliographical references (p. [267]-333) |
| Beschreibung: | VIII, 333 S. |
| ISBN: | 1905221045 |
Internformat
MARC
| LEADER | 00000nam a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV022447962 | ||
| 003 | DE-604 | ||
| 005 | 20070820 | ||
| 007 | t | ||
| 008 | 070531s2006 xxk |||| 00||| eng d | ||
| 010 | |a 2007405525 | ||
| 016 | 7 | |a LO 2007405525 |2 DE-101 | |
| 020 | |a 1905221045 |9 1-905221-04-5 | ||
| 035 | |a (DE-599)DNB 2007405525 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 044 | |a xxk |c GB | ||
| 049 | |a DE-M382 | ||
| 050 | 0 | |a K4610 | |
| 100 | 1 | |a Gad, Mohamed Omar |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Representational fairness in WTO rule-making |b negotiating, implementing, and disputing the TRIPS pharmaceutical-related provisions |c Mohamed Omar Gad |
| 246 | 1 | 3 | |a Representational fairness in W.T.O. rule-making |
| 264 | 1 | |a London |b British Institute of International and Comparative Law |c 2006 | |
| 264 | 1 | |a [Dallas, Tex.] |b SMU Dedman School of Law | |
| 300 | |a VIII, 333 S. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 500 | |a At head of title: British Institute of International and Comparative Law and SMU Dedman School of Law (SMU-London Forum Initiative). | ||
| 500 | |a Includes bibliographical references (p. [267]-333) | ||
| 630 | 0 | 4 | |a Agreement on Trade-Related Aspects of Intellectual Property Rights |d (1994) |
| 650 | 4 | |a World Trade Organization |x Rules and practice | |
| 650 | 4 | |a Drugs |x Patents | |
| 650 | 4 | |a Patents (International law) | |
| 856 | 4 | 2 | |m GBV Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=015655902&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-015655902 | ||
Datensatz im Suchindex
| _version_ | 1804136526492205056 |
|---|---|
| adam_text | BRITISH INSTITUTE OF INTERNATIONAL AND COMPARATIVE LAW AND SMU DEDMAN
SCHOOL OF LAW (SMU*LONDON FORUM INITIATIVE) REPRESENTATIONAL FAIRNESS IN
WTO RULE-MAKING NEGOTIATING, IMPLEMENTING, AND DISPUTING THE TRIPS
PHARMACEUTICAL-RELATED PROVISIONS MOHAMED OMAR GAD BRITISH INSTITUTE OF
INTERNATIONAL AND COMPARATIVE LAW THE SMU DEDMAN SCHOOL OF LAW
WWW.LAW.SMU.EDU CONTENTS LIST OF TABLES AND DIAGRAMS IX PART ONE:
MULTINATIONAL ENTERPRISES, DEVELOPING COUNTRIES, INTERNATIONAL
RULE-MAKING, AND THE TRIPS AGREEMENT 1 CHAPTER 1: INTRODUCTION 3 (I)
STAKEHOLDERS AND THE DIFFERING PERSPECTIVES 5 (A) MULTINATIONAL
ENTERPRISES PERSPECTIVE 5 (B) DEVELOPING COUNTRIES PERSPECTIVE 6 (C)
INDUSTRIALIZED COUNTRIES PERSPECTIVE 6 (D) WORLD TRADE ORGANIZATION
PERSPECTIVE 9 (E) OTHER PERSPECTIVES 10 (II) SIGNIFICANCE OF THE PROBLEM
10 (III) APPROACH TO THE PROBLEM 13 CHAPTER 2: INTERNATIONAL
RULE-MAKING: A MULTI-DISCIPLINARY EVALUATION 17 (I) DEFINING
TREATY-MAKING 18 (II) THE VIEW OF INTERNATIONAL LEGAL THEORY 21 (IE)
THE VIEW FROM INTERNATIONAL RELATIONS THEORY 25 (IV) THE VIEW FROM A
REGULATION THEORY PERSPECTIVE 29 CHAPTER 3: INFLUENCE OF MNES ON
INTERNATIONAL ECONOMIC REGULATION 33 (I) DEFINING MULTINATIONAL
ENTERPRISES 33 (II) MULTINATIONAL ENTERPRISES AS POLITICAL ACTORS 35
CHAPTER 4: PATENT PROTECTION AND THE TRIPS AGREEMENT 43 (I) AN
INTRODUCTION TO PATENT PROTECTION 43 (II) THE TRIPS AGREEMENT 46 (A)
GENERAL PROVISIONS 46 (B) STANDARDS FOR PATENT PROTECTION 52 (C) OTHER
RELEVANT PROVISIONS 60 VI CONTENTS PART TWO: TOP-DOWN RULE-MAKING: THE
FLAWED URUGUAY ROUND NEGOTIATIONS OF THE TRIPS PHARMACEUTICAL-RELATED
PROVISIONS 65 CHAPTER 5: PHARMACEUTICAL MNES PATENT REGIME PREFERENCES
69 (I) PHARMACEUTICAL MNES INTERESTS 69 (A) JUSTIFICATIONS, INTERESTS,
AND CONCERNS OF PHARMACEUTICAL MNES 70 (B) IDENTIFYING THE PROBLEM
ISSUES IN INTERNATIONAL PATENT PROTECTION 74 (II) MOBILIZING FOR
INTERNATIONAL PATENT LAW REFORM 78 (A) THE BILATERAL APPROACH: LOBBYING
THE KEY PLAYER(S) 78 (B) THE MULTILATERAL APPROACH: PHARMACEUTICAL MNES
AND THE TRIPS PATENT NEGOTIATIONS 87 CHAPTER 6: THE TRIPS PATENT
NEGOTIATIONS 93 (I) GATT AS A FORUM FOR NEGOTIATIONS ON IP 93 (A)
BACKGROUND TO THE CHOICE OF GATT AS A FORUM 93 (B) STRUCTURE OF THE
TRIPS NEGOTIATIONS 96 (II) NEGOTIATING THE PATENT PROVISIONS 97 (A)
INITIAL PHASE (1987-8) 98 (B) MID-TERM REVIEW (DECEMBER 1988-APRIL 1989)
106 (C) RESUMPTION OF NEGOTIATIONS (MID-1989-EARLY 1990) 108 (D) THE
DRAFT TEXTS HI (E) THE FINAL TRIPS NEGOTIATIONS 118 PART THREE: IMPACT
OF TRIPS IMPLEMENTATION ON DEVELOPING COUNTRY LAW AND POLICY 123 CHAPTER
7: STATUS OF DC LAW PRE-TRIPS IMPLEMENTATION 125 (I) GENERAL PROVISIONS
126 (A) PATENTABILITY REQUIREMENTS AND EXCLUSIONS FROM PATENTABILITY 126
(B) SCOPE OF RIGHTS CONFERRED 127 (II) COMPULSORY LICENSING AND WORKING
REQUIREMENTS 128 CHAPTER 8: PERSPECTIVES ON TRIPS IMPLEMENTATION 133 (I)
PERSPECTIVES OF DCS AND THEIR STAKEHOLDERS 134 (A) CONCERNS OVER THE
EFFECTS OF THE TRIPS RULE- MAKING PROCESS 134 (B) CONCERNS OVER SPECIFIC
TRIPS IMPLICATIONS 138 (II) PERSPECTIVE OF THE PHARMACEUTICAL MNES 141
CONTENTS VII (III) PERSPECTIVES OF THE ICS 144 (IV) OTHER PERSPECTIVES
148 CHAPTER 9: TRIPS IMPLEMENTATION PROCESS: THE CASE OF EGYPT 151 (I)
IC AND MNE CONCERNS AND PRESSURE ON EGYPT 154 (A) CONCERNS OF THE
PHARMACEUTICAL MNES 154 (B) US CONCERNS AND PRESSURE 155 (II) TRIPS
COUNCIL REVIEW OF EGYPT S LEGISLATION 158 (III) DRAFTING THE NEW
EGYPTIAN IP LAW 162 (A) DRAFTING AT THE EXECUTIVE BRANCH 162 (B)
DRAFTING AT THE LEGISLATIVE BRANCH 164 (C) CONTENTIOUS ISSUES 166
CHAPTER 10: STATUS OF DC LAW POST-TRIPS IMPLEMENTATION 171 (I)
TRANSITIONAL PROVISIONS 171 (II) GENERAL PROVISIONS 174 (A)
PATENTABILITY REQUIREMENTS AND EXCLUSIONS FROM PATENTABILITY 174 (B)
RIGHTS CONFERRED AND EXCEPTIONS 175 (HI) COMPULSORY LICENSING AND
WORKING REQUIREMENTS 176 PART FOUR: RETORTING FROM THE BOTTOM-UP :
DISPUTES AND CHALLENGES OVER THE IMPLEMENTATION AND INTERPRETATION OF
THE TRIPS PHARMACEUTICAL-RELATED PROVISIONS 181 CHAPTER 11: DISPUTES
UNDER THE WTO DSU MECHANISM 187 (I) INDIA DISPUTES 190 (II) ARGENTINA
CONSULTATIONS 195 (III) BRAZIL CONSULTATIONS 197 CHAPTER 12: DISPUTES AT
THE DOMESTIC AND BILATERAL LEVELS 201 (I) ADDRESSING THE ACCESS TO
MEDICINE DILEMMA 202 (II) BRAZIL S AIDS TREATMENT PROGRAMME 206 (A)
PRESSURE ON BRAZIL S POLICY 206 (B) COUNTERING US PRESSURE 208 (C)
TACKLING THE PHARMACEUTICAL MNES 209 (III) SOUTH AFRICA S MEDICINES
AMENDMENT ACT 211 (A) PHARMACEUTICAL MNES AND IC PRESSURES 213 (B)
LAWSUIT AGAINST THE GOVERNMENT OF SOUTH AFRICA 217 (C) NGOS RETORTING
ACTION 218 VIII CONTENTS CHAPTER 13: CHALLENGES AT THE WTO S POLITICAL
ORGANS 223 (I) GENESIS OF WTO ACTION 223 (II) STAKEHOLDERS POSITIONS
226 (A) DEVELOPING COUNTRIES POSITION 226 (B) INDUSTRIALIZED COUNTRIES
POSITIONS 231 (III) CONTESTATIONS AND DEVELOPMENTS 235 (A) SCOPE OF THE
DECLARATION 236 (B) DECLARATORY LANGUAGE 236 (C) TRIPS PROVISIONS
COVERED 237 (D) DEVELOPMENTS AND THE CHAIRMAN S DRAFT 239 (IV) DOHA
DECLARATION ON TRIPS AND PUBLIC HEALTH AND ITS AFTERMATH 241 (A)
UNDERSTANDING THE DECLARATION 241 (B) SIGNIFICANCE OF THE DECLARATION
243 PART FIVE: TOWARDS A BETTER PLAYING-FIELD 247 CHAPTER 14: THE TWIN
DYNAMIC OF TOP-DOWN RULE-MAKING AND BOTTOM-UP RETORTING ACTION 249
(I) TRIPS PATENT NEGOTIATIONS: TOP-DOWN RULE-MAKING 250 (A)
PHARMACEUTICAL MNES AND THE TRIPS PATENT NEGOTIATIONS OUTCOME 250 (B)
IMPLICATIONS OF THE TRIPS NEGOTIATIONS ON PATENTS 252 (II) TRIPS
IMPLEMENTATION AND DISPUTES: BOTTOM-UP RETORTING 253 CHAPTER 15:
SUGGESTIONS TOWARDS A VIABLE LEVEL OF REPRESENTATIONAL FAIRNESS 257 (I)
DEVELOPING COUNTRIES ACTION 258 (II) BALANCING NON-STATE ACTORS
INVOLVEMENT 260 (III) DC-MNE DIALOGUE 262 (IV) ISSUE LINKAGE AND
CONSIDERATIONS OF HUMAN RIGHTS 264 BIBLIOGRAPHY 267 INTERNATIONAL
TREATIES AND AGREEMENTS 267 LEGISLATION BY COUNTRY 267 WTO CASES 269 WTO
DOCUMENTS 269 TRIPS NEGOTIATIONS DOCUMENTS 272 GOVERNMENT DOCUMENTS 288
INTERVIEWS 295 SECONDARY SOURCES 296 LIST OF TABLES AND DIAGRAMS DIAGRAM
1.1: CONCEPTUAL VIEW OF THE TRIPS AGREEMENT S EFFECTS ON DC PUBLIC
POLICY 7 TABLE 1.1: SELECTED DISPUTES AND PRESSURES THAT HAVE ARISEN
CONCERNING PRODUCT PATENT PROTECTION FOR PHARMACEUTICALS IN FIVE
DEVELOPING COUNTRIES SINCE THE MID-1980S 8 TABLE 5.1: R&D EXPENDITURES
IN THE AREA OF DRUGS AND MEDICINES FOR MAJOR OECD COUNTRIES AND THE EU
1976-96 (IN MILLIONS OF PPP DOLLARS AT CURRENT PRICES) 73 TABLE 6.1:
COMPARISON OF PATENT STANDARDS ADVOCATED IN 1988 SUBMISSIONS OF THE EC,
JAPAN, US, AND THE TRILATERAL REPORT (IPC-KEIDANREN-UNICE) 103 TABLE
6.2: MAIN DIFFERENCES ON STANDARDS OF PATENT PROTECTION COMPARED TO THE
1988 SUBMISSIONS 113 TABLE 8.1: USTR SPECIAL 301 DESIGNATION OF SELECTED
DCS (1995-2002) 147 TABLE 9.1: MAIN REQUIREMENTS FOR IMPLEMENTING THE
PHARMACEUTICAL- RELATED TRIPS PROVISIONS AND CORRESPONDING ACTION IN
EGYPT 152 TABLE 9.2: QUESTIONS POSED BY WTO MEMBERS ON EGYPT S IPR
REGIME 159 TABLE 10.1: SUMMARY OF SELECTED DISPUTES AND CHALLENGES
INVOLVING DCS AND NGOS ON TRIPS REGIME 184 TABLE 11.1: SELECTE D WTO
REQUESTS FOR CONSULTATIONS RELATING TO TRIPS PATENT PROVISIONS INVOLVING
DEVELOPING COUNTRIES 188 TABLE 13.1: DEVELOPING COUNTRIES
INTERPRETATIONS OF THE FLEXIBILITIES INHERENT IN TRIPS PROVISIONS
RELATING TO PUBLIC HEALTH 228
|
| adam_txt |
BRITISH INSTITUTE OF INTERNATIONAL AND COMPARATIVE LAW AND SMU DEDMAN
SCHOOL OF LAW (SMU*LONDON FORUM INITIATIVE) REPRESENTATIONAL FAIRNESS IN
WTO RULE-MAKING NEGOTIATING, IMPLEMENTING, AND DISPUTING THE TRIPS
PHARMACEUTICAL-RELATED PROVISIONS MOHAMED OMAR GAD BRITISH INSTITUTE OF
INTERNATIONAL AND COMPARATIVE LAW THE SMU DEDMAN SCHOOL OF LAW
WWW.LAW.SMU.EDU CONTENTS LIST OF TABLES AND DIAGRAMS IX PART ONE:
MULTINATIONAL ENTERPRISES, DEVELOPING COUNTRIES, INTERNATIONAL
RULE-MAKING, AND THE TRIPS AGREEMENT 1 CHAPTER 1: INTRODUCTION 3 (I)
STAKEHOLDERS AND THE DIFFERING PERSPECTIVES 5 (A) MULTINATIONAL
ENTERPRISES' PERSPECTIVE 5 (B) DEVELOPING COUNTRIES' PERSPECTIVE 6 (C)
INDUSTRIALIZED COUNTRIES' PERSPECTIVE 6 (D) WORLD TRADE ORGANIZATION
PERSPECTIVE 9 (E) OTHER PERSPECTIVES 10 (II) SIGNIFICANCE OF THE PROBLEM
10 (III) APPROACH TO THE PROBLEM 13 CHAPTER 2: INTERNATIONAL
RULE-MAKING: A MULTI-DISCIPLINARY EVALUATION 17 (I) DEFINING
'TREATY-MAKING' 18 (II) THE VIEW OF INTERNATIONAL LEGAL THEORY 21 (IE)
THE VIEW FROM INTERNATIONAL RELATIONS THEORY 25 (IV) THE VIEW FROM A
REGULATION THEORY PERSPECTIVE 29 CHAPTER 3: INFLUENCE OF MNES ON
INTERNATIONAL ECONOMIC REGULATION 33 (I) DEFINING MULTINATIONAL
ENTERPRISES 33 (II) MULTINATIONAL ENTERPRISES AS POLITICAL ACTORS 35
CHAPTER 4: PATENT PROTECTION AND THE TRIPS AGREEMENT 43 (I) AN
INTRODUCTION TO PATENT PROTECTION 43 (II) THE TRIPS AGREEMENT 46 (A)
GENERAL PROVISIONS 46 (B) STANDARDS FOR PATENT PROTECTION 52 (C) OTHER
RELEVANT PROVISIONS 60 VI CONTENTS PART TWO: 'TOP-DOWN' RULE-MAKING: THE
FLAWED URUGUAY ROUND NEGOTIATIONS OF THE TRIPS PHARMACEUTICAL-RELATED
PROVISIONS 65 CHAPTER 5: PHARMACEUTICAL MNES PATENT REGIME PREFERENCES
69 (I) PHARMACEUTICAL MNES INTERESTS 69 (A) JUSTIFICATIONS, INTERESTS,
AND CONCERNS OF PHARMACEUTICAL MNES 70 (B) IDENTIFYING THE PROBLEM
ISSUES IN INTERNATIONAL PATENT PROTECTION 74 (II) MOBILIZING FOR
INTERNATIONAL PATENT LAW REFORM 78 (A) THE BILATERAL APPROACH: LOBBYING
THE KEY PLAYER(S) 78 (B) THE MULTILATERAL APPROACH: PHARMACEUTICAL MNES
AND THE TRIPS PATENT NEGOTIATIONS 87 CHAPTER 6: THE TRIPS PATENT
NEGOTIATIONS 93 (I) GATT AS A FORUM FOR NEGOTIATIONS ON IP 93 (A)
BACKGROUND TO THE CHOICE OF GATT AS A FORUM 93 (B) STRUCTURE OF THE
TRIPS NEGOTIATIONS 96 (II) NEGOTIATING THE PATENT PROVISIONS 97 (A)
INITIAL PHASE (1987-8) 98 (B) MID-TERM REVIEW (DECEMBER 1988-APRIL 1989)
106 (C) RESUMPTION OF NEGOTIATIONS (MID-1989-EARLY 1990) 108 (D) THE
DRAFT TEXTS HI (E) THE FINAL TRIPS NEGOTIATIONS 118 PART THREE: IMPACT
OF TRIPS IMPLEMENTATION ON DEVELOPING COUNTRY LAW AND POLICY 123 CHAPTER
7: STATUS OF DC LAW PRE-TRIPS IMPLEMENTATION 125 (I) GENERAL PROVISIONS
126 (A) PATENTABILITY REQUIREMENTS AND EXCLUSIONS FROM PATENTABILITY 126
(B) SCOPE OF RIGHTS CONFERRED 127 (II) COMPULSORY LICENSING AND WORKING
REQUIREMENTS 128 CHAPTER 8: PERSPECTIVES ON TRIPS IMPLEMENTATION 133 (I)
PERSPECTIVES OF DCS AND THEIR STAKEHOLDERS 134 (A) CONCERNS OVER THE
EFFECTS OF THE TRIPS RULE- MAKING PROCESS 134 (B) CONCERNS OVER SPECIFIC
TRIPS IMPLICATIONS 138 (II) PERSPECTIVE OF THE PHARMACEUTICAL MNES 141
CONTENTS VII (III) PERSPECTIVES OF THE ICS 144 (IV) OTHER PERSPECTIVES
148 CHAPTER 9: TRIPS IMPLEMENTATION PROCESS: THE CASE OF EGYPT 151 (I)
IC AND MNE CONCERNS AND PRESSURE ON EGYPT 154 (A) CONCERNS OF THE
PHARMACEUTICAL MNES 154 (B) US CONCERNS AND PRESSURE 155 (II) TRIPS
COUNCIL REVIEW OF EGYPT'S LEGISLATION 158 (III) DRAFTING THE NEW
EGYPTIAN IP LAW 162 (A) DRAFTING AT THE EXECUTIVE BRANCH 162 (B)
DRAFTING AT THE LEGISLATIVE BRANCH 164 (C) CONTENTIOUS ISSUES 166
CHAPTER 10: STATUS OF DC LAW POST-TRIPS IMPLEMENTATION 171 (I)
TRANSITIONAL PROVISIONS 171 (II) GENERAL PROVISIONS 174 (A)
PATENTABILITY REQUIREMENTS AND EXCLUSIONS FROM PATENTABILITY 174 (B)
RIGHTS CONFERRED AND EXCEPTIONS 175 (HI) COMPULSORY LICENSING AND
WORKING REQUIREMENTS 176 PART FOUR: RETORTING FROM THE 'BOTTOM-UP':
DISPUTES AND CHALLENGES OVER THE IMPLEMENTATION AND INTERPRETATION OF
THE TRIPS PHARMACEUTICAL-RELATED PROVISIONS 181 CHAPTER 11: DISPUTES
UNDER THE WTO DSU MECHANISM 187 (I) INDIA DISPUTES 190 (II) ARGENTINA
CONSULTATIONS 195 (III) BRAZIL CONSULTATIONS 197 CHAPTER 12: DISPUTES AT
THE DOMESTIC AND BILATERAL LEVELS 201 (I) ADDRESSING THE ACCESS TO
MEDICINE DILEMMA 202 (II) BRAZIL'S AIDS TREATMENT PROGRAMME 206 (A)
PRESSURE ON BRAZIL'S POLICY 206 (B) COUNTERING US PRESSURE 208 (C)
TACKLING THE PHARMACEUTICAL MNES 209 (III) SOUTH AFRICA'S MEDICINES
AMENDMENT ACT 211 (A) PHARMACEUTICAL MNES AND IC PRESSURES 213 (B)
LAWSUIT AGAINST THE GOVERNMENT OF SOUTH AFRICA 217 (C) NGOS'RETORTING
ACTION 218 VIII CONTENTS CHAPTER 13: CHALLENGES AT THE WTO'S POLITICAL
ORGANS 223 (I) GENESIS OF WTO ACTION 223 (II) STAKEHOLDERS' POSITIONS
226 (A) DEVELOPING COUNTRIES' POSITION 226 (B) INDUSTRIALIZED COUNTRIES'
POSITIONS 231 (III) CONTESTATIONS AND DEVELOPMENTS 235 (A) SCOPE OF THE
DECLARATION 236 (B) DECLARATORY LANGUAGE 236 (C) TRIPS PROVISIONS
COVERED 237 (D) DEVELOPMENTS AND THE CHAIRMAN'S DRAFT 239 (IV) DOHA
DECLARATION ON TRIPS AND PUBLIC HEALTH AND ITS AFTERMATH 241 (A)
UNDERSTANDING THE DECLARATION 241 (B) SIGNIFICANCE OF THE DECLARATION
243 PART FIVE: TOWARDS A BETTER 'PLAYING-FIELD' 247 CHAPTER 14: THE TWIN
DYNAMIC OF 'TOP-DOWN' RULE-MAKING AND 'BOTTOM-UP' RETORTING ACTION 249
(I) TRIPS PATENT NEGOTIATIONS: TOP-DOWN RULE-MAKING 250 (A)
PHARMACEUTICAL MNES AND THE TRIPS PATENT NEGOTIATIONS OUTCOME 250 (B)
IMPLICATIONS OF THE TRIPS NEGOTIATIONS ON PATENTS 252 (II) TRIPS
IMPLEMENTATION AND DISPUTES: BOTTOM-UP RETORTING 253 CHAPTER 15:
SUGGESTIONS TOWARDS A VIABLE LEVEL OF REPRESENTATIONAL FAIRNESS 257 (I)
DEVELOPING COUNTRIES' ACTION 258 (II) BALANCING NON-STATE ACTORS'
INVOLVEMENT 260 (III) DC-MNE DIALOGUE 262 (IV) ISSUE LINKAGE AND
CONSIDERATIONS OF HUMAN RIGHTS 264 BIBLIOGRAPHY 267 INTERNATIONAL
TREATIES AND AGREEMENTS 267 LEGISLATION BY COUNTRY 267 WTO CASES 269 WTO
DOCUMENTS 269 TRIPS NEGOTIATIONS DOCUMENTS 272 GOVERNMENT DOCUMENTS 288
INTERVIEWS 295 SECONDARY SOURCES 296 LIST OF TABLES AND DIAGRAMS DIAGRAM
1.1: CONCEPTUAL VIEW OF THE TRIPS AGREEMENT'S EFFECTS ON DC PUBLIC
POLICY 7 TABLE 1.1: SELECTED DISPUTES AND PRESSURES THAT HAVE ARISEN
CONCERNING PRODUCT PATENT PROTECTION FOR PHARMACEUTICALS IN FIVE
DEVELOPING COUNTRIES SINCE THE MID-1980S 8 TABLE 5.1: R&D EXPENDITURES
IN THE AREA OF DRUGS AND MEDICINES FOR MAJOR OECD COUNTRIES AND THE EU
1976-96 (IN MILLIONS OF PPP DOLLARS AT CURRENT PRICES) 73 TABLE 6.1:
COMPARISON OF PATENT STANDARDS ADVOCATED IN 1988 SUBMISSIONS OF THE EC,
JAPAN, US, AND THE TRILATERAL REPORT (IPC-KEIDANREN-UNICE) 103 TABLE
6.2: MAIN DIFFERENCES ON STANDARDS OF PATENT PROTECTION COMPARED TO THE
1988 SUBMISSIONS 113 TABLE 8.1: USTR SPECIAL 301 DESIGNATION OF SELECTED
DCS (1995-2002) 147 TABLE 9.1: MAIN REQUIREMENTS FOR IMPLEMENTING THE
PHARMACEUTICAL- RELATED TRIPS PROVISIONS AND CORRESPONDING ACTION IN
EGYPT 152 TABLE 9.2: QUESTIONS POSED BY WTO MEMBERS ON EGYPT'S IPR
REGIME 159 TABLE 10.1: SUMMARY OF SELECTED DISPUTES AND CHALLENGES
INVOLVING DCS AND NGOS ON TRIPS REGIME 184 TABLE 11.1: SELECTE D WTO
REQUESTS FOR CONSULTATIONS RELATING TO TRIPS PATENT PROVISIONS INVOLVING
DEVELOPING COUNTRIES 188 TABLE 13.1: DEVELOPING COUNTRIES'
INTERPRETATIONS OF THE FLEXIBILITIES INHERENT IN TRIPS PROVISIONS
RELATING TO PUBLIC HEALTH 228 |
| any_adam_object | 1 |
| any_adam_object_boolean | 1 |
| author | Gad, Mohamed Omar |
| author_facet | Gad, Mohamed Omar |
| author_role | aut |
| author_sort | Gad, Mohamed Omar |
| author_variant | m o g mo mog |
| building | Verbundindex |
| bvnumber | BV022447962 |
| callnumber-first | K - Law |
| callnumber-label | K4610 |
| callnumber-raw | K4610 |
| callnumber-search | K4610 |
| callnumber-sort | K 44610 |
| callnumber-subject | K - General Law |
| ctrlnum | (DE-599)DNB 2007405525 |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01717nam a2200397zc 4500</leader><controlfield tag="001">BV022447962</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20070820 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">070531s2006 xxk |||| 00||| eng d</controlfield><datafield tag="010" ind1=" " ind2=" "><subfield code="a">2007405525</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">LO 2007405525</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1905221045</subfield><subfield code="9">1-905221-04-5</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DNB 2007405525</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">xxk</subfield><subfield code="c">GB</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-M382</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">K4610</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Gad, Mohamed Omar</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Representational fairness in WTO rule-making</subfield><subfield code="b">negotiating, implementing, and disputing the TRIPS pharmaceutical-related provisions</subfield><subfield code="c">Mohamed Omar Gad</subfield></datafield><datafield tag="246" ind1="1" ind2="3"><subfield code="a">Representational fairness in W.T.O. rule-making</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">London</subfield><subfield code="b">British Institute of International and Comparative Law</subfield><subfield code="c">2006</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">[Dallas, Tex.]</subfield><subfield code="b">SMU Dedman School of Law</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">VIII, 333 S.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">At head of title: British Institute of International and Comparative Law and SMU Dedman School of Law (SMU-London Forum Initiative).</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references (p. [267]-333)</subfield></datafield><datafield tag="630" ind1="0" ind2="4"><subfield code="a">Agreement on Trade-Related Aspects of Intellectual Property Rights</subfield><subfield code="d">(1994)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">World Trade Organization</subfield><subfield code="x">Rules and practice</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drugs</subfield><subfield code="x">Patents</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Patents (International law)</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">GBV Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=015655902&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-015655902</subfield></datafield></record></collection> |
| id | DE-604.BV022447962 |
| illustrated | Not Illustrated |
| index_date | 2024-07-02T17:35:17Z |
| indexdate | 2024-07-09T20:57:48Z |
| institution | BVB |
| isbn | 1905221045 |
| language | English |
| lccn | 2007405525 |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-015655902 |
| open_access_boolean | |
| owner | DE-M382 |
| owner_facet | DE-M382 |
| physical | VIII, 333 S. |
| publishDate | 2006 |
| publishDateSearch | 2006 |
| publishDateSort | 2006 |
| publisher | British Institute of International and Comparative Law SMU Dedman School of Law |
| record_format | marc |
| spelling | Gad, Mohamed Omar Verfasser aut Representational fairness in WTO rule-making negotiating, implementing, and disputing the TRIPS pharmaceutical-related provisions Mohamed Omar Gad Representational fairness in W.T.O. rule-making London British Institute of International and Comparative Law 2006 [Dallas, Tex.] SMU Dedman School of Law VIII, 333 S. txt rdacontent n rdamedia nc rdacarrier At head of title: British Institute of International and Comparative Law and SMU Dedman School of Law (SMU-London Forum Initiative). Includes bibliographical references (p. [267]-333) Agreement on Trade-Related Aspects of Intellectual Property Rights (1994) World Trade Organization Rules and practice Drugs Patents Patents (International law) GBV Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=015655902&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Gad, Mohamed Omar Representational fairness in WTO rule-making negotiating, implementing, and disputing the TRIPS pharmaceutical-related provisions Agreement on Trade-Related Aspects of Intellectual Property Rights (1994) World Trade Organization Rules and practice Drugs Patents Patents (International law) |
| title | Representational fairness in WTO rule-making negotiating, implementing, and disputing the TRIPS pharmaceutical-related provisions |
| title_alt | Representational fairness in W.T.O. rule-making |
| title_auth | Representational fairness in WTO rule-making negotiating, implementing, and disputing the TRIPS pharmaceutical-related provisions |
| title_exact_search | Representational fairness in WTO rule-making negotiating, implementing, and disputing the TRIPS pharmaceutical-related provisions |
| title_exact_search_txtP | Representational fairness in WTO rule-making negotiating, implementing, and disputing the TRIPS pharmaceutical-related provisions |
| title_full | Representational fairness in WTO rule-making negotiating, implementing, and disputing the TRIPS pharmaceutical-related provisions Mohamed Omar Gad |
| title_fullStr | Representational fairness in WTO rule-making negotiating, implementing, and disputing the TRIPS pharmaceutical-related provisions Mohamed Omar Gad |
| title_full_unstemmed | Representational fairness in WTO rule-making negotiating, implementing, and disputing the TRIPS pharmaceutical-related provisions Mohamed Omar Gad |
| title_short | Representational fairness in WTO rule-making |
| title_sort | representational fairness in wto rule making negotiating implementing and disputing the trips pharmaceutical related provisions |
| title_sub | negotiating, implementing, and disputing the TRIPS pharmaceutical-related provisions |
| topic | Agreement on Trade-Related Aspects of Intellectual Property Rights (1994) World Trade Organization Rules and practice Drugs Patents Patents (International law) |
| topic_facet | Agreement on Trade-Related Aspects of Intellectual Property Rights (1994) World Trade Organization Rules and practice Drugs Patents Patents (International law) |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=015655902&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT gadmohamedomar representationalfairnessinwtorulemakingnegotiatingimplementinganddisputingthetripspharmaceuticalrelatedprovisions AT gadmohamedomar representationalfairnessinwtorulemaking |